Clayton Financial Group LLC Buys Shares of 13,893 Mesoblast Limited (NASDAQ:MESO)

Clayton Financial Group LLC bought a new position in Mesoblast Limited (NASDAQ:MESO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 13,893 shares of the company’s stock, valued at approximately $275,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Mesoblast during the second quarter valued at $562,000. Ballentine Partners LLC acquired a new stake in Mesoblast in the fourth quarter valued at $222,000. Signaturefd LLC raised its position in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Creative Planning acquired a new position in Mesoblast during the 3rd quarter worth about $147,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Price Performance

Shares of Mesoblast stock opened at $20.40 on Wednesday. The business has a 50-day simple moving average of $16.04 and a 200 day simple moving average of $10.81. Mesoblast Limited has a one year low of $1.75 and a one year high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Wall Street Analysts Forecast Growth

MESO has been the subject of a number of analyst reports. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. Piper Sandler boosted their price target on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.50.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.